Metoclopramidum Polpharma

Metoclopramide, the active ingredient in Metoclopramidum Polpharma, is a dopamine antagonist presented as an oral tablet for oral use. It is employed to treat nausea and vomiting, gastroparesis, and gastro‑esophageal reflux disease in adult patients. GNH USA supplies Metoclopramidum Polpharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metoclopramide acts on the dopaminergic pathways that trigger nausea and impair gastric motility. - Nausea and vomiting: reduces episodes of acute and chemotherapy‑induced nausea. - Gastroparesis: enhances gastric emptying and relieves associated symptoms. - Gastro‑esophageal reflux disease (GERD): improves lower esophageal sphincter tone and reduces reflux episodes.

Metoclopramide may cause a range of adverse reactions.

Common Side Effects: - Drowsiness: mild sedation that may affect alertness. - Fatigue: generalized tiredness reported by some patients. - Diarrhea: increased bowel movements or loose stools. - Headache: mild to moderate head pain.

Serious or Rare Side Effects: - Extrapyramidal symptoms: muscle rigidity, tremor, or dystonia. - Tardive dyskinesia: irreversible involuntary movements with long‑term use. - Neuroleptic malignant syndrome: rare but life‑threatening hyperthermia and muscle breakdown.

Metoclopramide requires careful patient assessment and monitoring. - Renal function: assess before initiating therapy, especially in the elderly. - Extrapyramidal monitoring: watch for signs of dystonia or akathisia. - Hypersensitivity: discontinue if allergic reactions such as rash or swelling occur. - Elderly patients: use the lowest effective dose and limit duration. - Pregnancy and lactation: weigh potential benefits against uncertain risks. - Store at room temperature: keep in the original pack, protect from moisture.

Metoclopramide can interact with several drug classes, altering efficacy or safety.

Major Interactions (Avoid): - Antipsychotics (e.g., haloperidol): additive dopamine blockade may increase extrapyramidal risk. - Monoamine oxidase inhibitors: combined effect can precipitate severe hypertension. - CYP2D6 inhibitors (e.g., fluoxetine): may raise metoclopramide plasma levels.

Moderate Interactions (Monitor Closely): - Opioids: enhanced risk of constipation and reduced gastric motility. - Antihistamines: increased sedation. - Alcohol: may potentiate central nervous system depression.